Location: Home > Pharma China Web Edition
  • search
  • go
    • Regulatory News
    SFDA Takes Measures to Boost Production of Blood Coagulation Factor VIII 12/14/2007
    The SFDA said recently that it is finding ways to address the severe shortage of blood coagulation factor VIII, a medication needed by hemophiliacs across the country.

    There is currently an insufficient supply of blood plasma from which factor VIII is made. Official figures show that nationwide supplies of plasma fell by 50 percent last year. Currently, only three of China's 30 blood product manufacturers can and are making the clotting factor VIII, according to Yan Jiangying, spokeswoman for the SFDA.

    "Realizing the severe situation, we have taken a slew of countermeasures," Yan said. These include policies and other forms of support to help manufacturers use plasma more effectively, she said.

    "We have launched a trial to try and find new ways of maximizing the yield of limited sources," Yan said.

    The three firms, which are in Shanghai, Henan and Anhui, are given priority to making factor VIII.

    "To ease pressure on production and help redress the shortfall, we have worked with the Ministry of Health to provide the firms with additional supplies of plasma," Yan said.

    Chu Yuguang, a hemophiliac from Beijing and director of the Hemophilia Home of China, a volunteer civil society with more than 3,000 members, said: "The current supplies are enough to help just 5 percent of the country's 100,000 hemophiliacs."
    Relate News
    4/14/2010
  • MOH introduces new measures to promote awareness and treatment of hemophilia
    • 12/14/2007
  • SFDA Takes Measures to Boost Production of Blood Coagulation Factor VIII
    • 11/14/2007
  • Bayer Receives SFDA Approval for Kogenate FS
    • more
  • Site map | Contact Us | Links
  • © Wicon International Group